Johnson & Johnson, Janssen And Changzhou Yabang-QH Pharmachem To Jointly Establish Anti-Worm Drug Base
This article was originally published in PharmAsia News
Johnson & Johnson, Janssen Pharmaceutica NV and Changzhou Yabang-QH Pharmachem recently began construction of their co-designed raw pharmaceutical materials base in Changzhou High-tech District. Of the total investment of about RMB 57 million, the first phase will receive a RMB 35 million capital injection. The facility, which is compliant with European and U.S. GMP, will go into production within this year. At the same time, the center will apply for Europe COS and FDA authentication with Janssen's aid. When completed, the facility will be China's largest anti-worm drug production, research and export base. Most of the expanded products will go to global high-end markets such as the U.S., Europe and Australia. (Click her for more - Chinese Language)
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.